An immune-booster with broad-spectrum antiviral activity:

AIC649 is a proprietary inactivated parapoxvirus (iPPVO). It induces a natural, self-limiting immune response, while enhancing appropriate immune reactions against unrelated viruses. AIC649 is being developed as first-line therapy in combination with standard of care for patients chronically infected with Hepatitis B Virus (HBV). A Phase 1 trial was successfully completed with no safety concerns and a phase 1b/2a trial is in preparation. In pre-clinical experiments, AIC649 demonstrated broad anti-viral activity in prophylactic as well as treatment settings (e.g., against HBV, HCV, HSV, Influenza, HIV/SIV, SARS-CoV-2). AIC649 is thus currently additionally being investigated as a preemptive treatment for SARS-CoV-2 infection, with a pilot trial starting shortly. Moreover, a broad prophylactic use will be evaluated, including future viral pandemics of unknown origin.



  Partly funded by the German state of